Abstract
Purpose: The aim of this study was to establish a risk-stratification model integrating posttreatment metabolic response using the Deauville score and the pretreatment National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) in nodal PTCLs. Methods: We retrospectively analysed 326 patients with newly diagnosed nodal PTCLs between January 2005 and June 2016 and both baseline and posttreatment PET/CT data. The final model was validated using an independent prospective cohort of 79 patients. Results: Posttreatment Deauville score (1/2, 3, and 4/5) and the NCCN-IPI (low, low-intermediate, high-intermediate, and high) were independently associated with progression-free survival: for the Deauville score, the hazard ratios (HRs) were 1.00 vs. 2.16 (95% CI 1.47–3.18) vs. 7.86 (5.66–10.92), P < 0.001; and for the NCCN-IPI, the HRs were 1.00 vs. 2.31 (95% CI 1.20–4.41) vs. 4.42 (2.36–8.26) vs. 7.09 (3.57–14.06), P < 0.001. Based on these results, we developed a simplified three-group risk model comprising a low-risk group (low or low-intermediate NCCN-IPI with a posttreatment Deauville score of 1 or 2, or low NCCN-IPI with a Deauville score of 3), a high-risk group (high or high-intermediate NCCN-IPI with a Deauville score of 1/2 or 3, or low-intermediate NCCN-IPI with a Deauville score of 3), and a treatment failure group (Deauville score 4 or 5). This model was significantly associated with progression-free survival (5-year, 70.3%, 31.4%, and 4.7%; P < 0.001) and overall survival (5-year, 82.1%, 45.5%, and 14.7%; P < 0.001). Similar associations were also observed in the independent validation cohort. Conclusion: The risk-stratification model integrating posttreatment Deauville score and pretreatment NCCN-IPI is a powerful tool for predicting treatment failure in patients with nodal PTCLs.
| Original language | English |
|---|---|
| Pages (from-to) | 2274-2284 |
| Number of pages | 11 |
| Journal | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume | 45 |
| Issue number | 13 |
| DOIs | |
| Publication status | Published - 2018 Dec 1 |
Fingerprint
Keywords
- International prognostic index
- Peripheral T-cell lymphoma
- PET/CT
- Prognosis
- Treatment
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. / Yhim, Ho Young; Park, Yong; Han, Yeon Hee; Kim, Sungeun; Kang, Sae Ryung; Moon, Joon Ho; Jeong, Ju Hye; Shin, Ho Jin; Kim, Keunyoung; Choi, Yoon Seok; Kim, Kunho; Kim, Min Kyoung; Kong, Eunjung; Kim, Dae Sik; Eo, Jae Seon; Lee, Ji Hyun; Kang, Do Young; Lee, Won Sik; Lee, Seok Mo; Do, Young Rok; Ham, Jun Soo; Kim, Seok Jin; Kim, Won Seog; Choi, Joon Young; Yang, Deok Hwan; Kwak, Jae Yong.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, No. 13, 01.12.2018, p. 2274-2284.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score
AU - Yhim, Ho Young
AU - Park, Yong
AU - Han, Yeon Hee
AU - Kim, Sungeun
AU - Kang, Sae Ryung
AU - Moon, Joon Ho
AU - Jeong, Ju Hye
AU - Shin, Ho Jin
AU - Kim, Keunyoung
AU - Choi, Yoon Seok
AU - Kim, Kunho
AU - Kim, Min Kyoung
AU - Kong, Eunjung
AU - Kim, Dae Sik
AU - Eo, Jae Seon
AU - Lee, Ji Hyun
AU - Kang, Do Young
AU - Lee, Won Sik
AU - Lee, Seok Mo
AU - Do, Young Rok
AU - Ham, Jun Soo
AU - Kim, Seok Jin
AU - Kim, Won Seog
AU - Choi, Joon Young
AU - Yang, Deok Hwan
AU - Kwak, Jae Yong
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Purpose: The aim of this study was to establish a risk-stratification model integrating posttreatment metabolic response using the Deauville score and the pretreatment National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) in nodal PTCLs. Methods: We retrospectively analysed 326 patients with newly diagnosed nodal PTCLs between January 2005 and June 2016 and both baseline and posttreatment PET/CT data. The final model was validated using an independent prospective cohort of 79 patients. Results: Posttreatment Deauville score (1/2, 3, and 4/5) and the NCCN-IPI (low, low-intermediate, high-intermediate, and high) were independently associated with progression-free survival: for the Deauville score, the hazard ratios (HRs) were 1.00 vs. 2.16 (95% CI 1.47–3.18) vs. 7.86 (5.66–10.92), P < 0.001; and for the NCCN-IPI, the HRs were 1.00 vs. 2.31 (95% CI 1.20–4.41) vs. 4.42 (2.36–8.26) vs. 7.09 (3.57–14.06), P < 0.001. Based on these results, we developed a simplified three-group risk model comprising a low-risk group (low or low-intermediate NCCN-IPI with a posttreatment Deauville score of 1 or 2, or low NCCN-IPI with a Deauville score of 3), a high-risk group (high or high-intermediate NCCN-IPI with a Deauville score of 1/2 or 3, or low-intermediate NCCN-IPI with a Deauville score of 3), and a treatment failure group (Deauville score 4 or 5). This model was significantly associated with progression-free survival (5-year, 70.3%, 31.4%, and 4.7%; P < 0.001) and overall survival (5-year, 82.1%, 45.5%, and 14.7%; P < 0.001). Similar associations were also observed in the independent validation cohort. Conclusion: The risk-stratification model integrating posttreatment Deauville score and pretreatment NCCN-IPI is a powerful tool for predicting treatment failure in patients with nodal PTCLs.
AB - Purpose: The aim of this study was to establish a risk-stratification model integrating posttreatment metabolic response using the Deauville score and the pretreatment National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) in nodal PTCLs. Methods: We retrospectively analysed 326 patients with newly diagnosed nodal PTCLs between January 2005 and June 2016 and both baseline and posttreatment PET/CT data. The final model was validated using an independent prospective cohort of 79 patients. Results: Posttreatment Deauville score (1/2, 3, and 4/5) and the NCCN-IPI (low, low-intermediate, high-intermediate, and high) were independently associated with progression-free survival: for the Deauville score, the hazard ratios (HRs) were 1.00 vs. 2.16 (95% CI 1.47–3.18) vs. 7.86 (5.66–10.92), P < 0.001; and for the NCCN-IPI, the HRs were 1.00 vs. 2.31 (95% CI 1.20–4.41) vs. 4.42 (2.36–8.26) vs. 7.09 (3.57–14.06), P < 0.001. Based on these results, we developed a simplified three-group risk model comprising a low-risk group (low or low-intermediate NCCN-IPI with a posttreatment Deauville score of 1 or 2, or low NCCN-IPI with a Deauville score of 3), a high-risk group (high or high-intermediate NCCN-IPI with a Deauville score of 1/2 or 3, or low-intermediate NCCN-IPI with a Deauville score of 3), and a treatment failure group (Deauville score 4 or 5). This model was significantly associated with progression-free survival (5-year, 70.3%, 31.4%, and 4.7%; P < 0.001) and overall survival (5-year, 82.1%, 45.5%, and 14.7%; P < 0.001). Similar associations were also observed in the independent validation cohort. Conclusion: The risk-stratification model integrating posttreatment Deauville score and pretreatment NCCN-IPI is a powerful tool for predicting treatment failure in patients with nodal PTCLs.
KW - International prognostic index
KW - Peripheral T-cell lymphoma
KW - PET/CT
KW - Prognosis
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85050828172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050828172&partnerID=8YFLogxK
U2 - 10.1007/s00259-018-4093-1
DO - 10.1007/s00259-018-4093-1
M3 - Article
C2 - 30056546
AN - SCOPUS:85050828172
VL - 45
SP - 2274
EP - 2284
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
SN - 1619-7070
IS - 13
ER -